Search research articles
Contact Us
Filters
Showing results (81-90 of 115) with videos related to
Page
of 12
Sort By:
British Journal of Cancer
|
December 14, 2020
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma
Geoffrey I Shapiro, Patricia LoRusso, Afshin Dowlati, et al.
Leukemia
|
February 17, 2026
Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma
Daniel J Landsburg, Nancy Musoke, Caren Gentile, et al.
Haematologica
|
May 9, 2024
Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy
Chiara Tarantelli, David Wald, Nicolas Munz, et al.
Transplantation and Cellular Therapy
|
June 10, 2026
Neighborhood socioeconomic disadvantage and distance from treatment center do not impact survival outcomes of patients with non-Hodgkin lymphoma and multiple myeloma treated with CAR T-cell therapies
Agrima Mian, Rafaella Litvin, Danai Dima, et al.
Blood Advances
|
January 3, 2024
A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
Leland L Metheny, Ronald Sobecks, Christina Cho, et al.
Hematology (Amsterdam, Netherlands)
|
January 21, 2017
Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era
Adam G Starr, Paolo F Caimi, PingFu Fu, et al.
British Journal of Haematology
|
July 23, 2016
Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era
Adam G Starr, Paolo F Caimi, PingFu Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 19, 2023
PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial
Juan Pablo Alderuccio, Isildinha M Reis, Mehdi Hamadani, et al.
British Journal of Haematology
|
March 9, 2016
Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes
Adam G Starr, Paolo F Caimi, PingFu Fu, et al.
Frontiers in Immunology
|
August 28, 2020
Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma
Zachary Jackson, Anne Roe, Ashish Arunkumar Sharma, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 115) with videos related to
Sort By:
Page
of 12
British Journal of Cancer
|
December 14, 2020
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma
Geoffrey I Shapiro, Patricia LoRusso, Afshin Dowlati, et al.
Leukemia
|
February 17, 2026
Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma
Daniel J Landsburg, Nancy Musoke, Caren Gentile, et al.
Haematologica
|
May 9, 2024
Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy
Chiara Tarantelli, David Wald, Nicolas Munz, et al.
Transplantation and Cellular Therapy
|
June 10, 2026
Neighborhood socioeconomic disadvantage and distance from treatment center do not impact survival outcomes of patients with non-Hodgkin lymphoma and multiple myeloma treated with CAR T-cell therapies
Agrima Mian, Rafaella Litvin, Danai Dima, et al.
Blood Advances
|
January 3, 2024
A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
Leland L Metheny, Ronald Sobecks, Christina Cho, et al.
Hematology (Amsterdam, Netherlands)
|
January 21, 2017
Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era
Adam G Starr, Paolo F Caimi, PingFu Fu, et al.
British Journal of Haematology
|
July 23, 2016
Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era
Adam G Starr, Paolo F Caimi, PingFu Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 19, 2023
PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial
Juan Pablo Alderuccio, Isildinha M Reis, Mehdi Hamadani, et al.
British Journal of Haematology
|
March 9, 2016
Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes
Adam G Starr, Paolo F Caimi, PingFu Fu, et al.
Frontiers in Immunology
|
August 28, 2020
Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma
Zachary Jackson, Anne Roe, Ashish Arunkumar Sharma, et al.
Page
of 12